N-methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia?
Article first published online: 8 OCT 2004
Copyright © 1989 The American Neurological Association
Annals of Neurology
Volume 25, Issue 4, pages 398–403, April 1989
How to Cite
Albers, G. W., Goldberg, M. P. and Choi, D. W. (1989), N-methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia?. Ann Neurol., 25: 398–403. doi: 10.1002/ana.410250412
- Issue published online: 8 OCT 2004
- Article first published online: 8 OCT 2004
- Manuscript Accepted: 14 SEP 1988
- Manuscript Revised: 12 SEP 1988
- Manuscript Received: 15 JUL 1988
Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.